Roche’s exercise of its option concludes initial collaboration and further validates Dyno’s field-leading gene delivery platform and AI-powered sequence design technologies for therapeutic developers
Dyno to receive ...
The treatment has the potential to cure diseases, but high costs and a difficult delivery process have held it back.
Roche Holding AG is willing to pay more than $1 billion to solve one ...
New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets
Dyno to receive US$50 million upfront cash ...
